APPB-515

APPB-515 is an investigational, locally administered gene therapy being developed for the treatment of osteoarthritis, specifically targeting the knee joint. Developed by Applied Biologics, the program utilizes computational protein engineering, molecular biology, and gene delivery technologies to enable sustained expression of therapeutic proteins directly within the joint. The therapy is designed to address multiple biological processes associated with joint deterioration and cartilage degeneration, aiming to provide a disease-modifying approach to osteoarthritis. As of October 2026, APPB-515 is in preclinical development, with the successful manufacture of its first recombinant reference protein marking a key milestone toward lead candidate selection.